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Abstract
Fibrillin-1 is a large extracellular matrix glycoprotein which assembles to form 10^12 nm microfibrils in extracellular
matrix. Mutations in the human fibrillin-1 gene (FBN-1) cause the connective tissue disease Marfan syndrome and related
disorders, which are characterised by defects in the skeletal, cardiovascular and ocular systems of the body. Fibrillin-1 has a
striking modular organisation which is dominated by multiple tandem repeats of the calcium binding epidermal growth
factor-like (cbEGF) domain. This review focuses on recent studies which have investigated the structural and functional role
of calcium binding to cbEGF domains in fibrillin-1 and 10^12 nm microfibrils. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Human ¢brillin-1 is a 350 kDa calcium binding
glycoprotein, which is a major structural component
of 10^12 nm micro¢brils located in the extracellular
matrix of connective tissue [1]. Mutations in the ¢-
brillin-1 gene (FBN-1) cause the connective tissue
disease, the Marfan syndrome, and related disorders
[2]. Fibrillin-1 has a highly modular organisation
typical of many extracellular proteins (Fig. 1) [3].
There is striking repetition of two disulphide-rich
modules, the epidermal growth factor-like (EGF) do-
main and the transforming growth factor L binding
protein-like (TB or eight-cysteine) domain. Of the 47
EGF domains present within the protein, 43 are of
the Ca2 binding type (referred to as cbEGF do-
mains) [4,5]. Each of these is characterised by six
cysteine residues which normally disulphide bond in
a 1-3, 2-4, 5-6 arrangement and a calcium binding
consensus D/N-x-D/N-E/Q-xm-D/N*-xn-Y/F (where
m and n are variable and * indicates possible post-
translational L-hydroxylation) (Fig. 2) [6]. The calci-
um binding site has a pentagonal bipyramidal geom-
etry with six out of seven ligands provided by intra-
domain oxygen atoms [7]. These include both side
chain oxygen atoms and backbone carbonyl groups
(Fig. 2). Two residues which are part of the cbEGF
domain calcium binding consensus do not ligand di-
rectly to calcium but instead are involved in stabilis-
ing the structure of the calcium binding site itself.
The identity of the seventh ligand is unknown and
may be a water molecule or an interdomain or inter-
molecular protein ligand [7,8].
Fibrillin-1 cbEGF domains occur as multiple cop-
ies and, in most cases, each set of cbEGF repeats is
separated from the next by a TB domain. In addition
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to these module types there are two hybrid domains,
a proline-rich region and N- and C-termini with ho-
mology to other extracellular matrix proteins (Fig. 1)
[9]. A homologous protein ¢brillin-2 has been iden-
ti¢ed which has a similar domain organisation,
although the proline-rich region of ¢brillin-1 is re-
placed in ¢brillin-2 by a glycine-rich sequence [10].
Mutations in the FBN-2 gene lead to the connective
tissue disease, congenital contractural arachnodac-
tyly (CCA) [11]. This review will focus on recent
studies which have investigated the structural and
functional role of cbEGF domains in ¢brillin-1 and
the micro¢bril.
2. Production of cbEGFs for structure/function studies
The properties of ¢brillin-1, which include large
molecular weight, high sulphydryl content and rapid
incorporation into extracellular matrix and subse-
quent cross-linking, make it di⁄cult to obtain pure
protein preparations. Thus high resolution structural
analyses have been con¢ned to recombinant domain
fragments which contain the di¡erent module combi-
nations found within ¢brillin-1. Solving the structure
of a limited number of domain fragments should
enable the major portion of ¢brillin-1 structure to
be determined by homology modelling. Such struc-
tural information is a prerequisite to understanding
the functional e¡ects of ¢brillin mutations which lead
to disease.
The high disulphide content of ¢brillin-1 domains
can cause technical problems for the production of
large quantities of native protein from eukaryotic
cells for structural studies. However, production
methods have been developed which utilise an in
vitro refolding protocol to form the native disulphide
bond arrangement after puri¢cation of the domain in
its reduced form [12,13]. Thus large quantities of
puri¢ed peptide can be obtained using procaryotic
hosts, e.g. Escherichia coli, and de¢ned media can
be used to incorporate speci¢c labels (15N, 13C, 2H,
seleno-methionine) into the peptide sequence to facil-
itate structural studies. Both cbEGF and TB do-
mains refold e⁄ciently using such a system [13^16].
Fibrillin cbEGF domains produced by this system
lack post-translational modi¢cations that may be as-
sociated with this type of domain (N- and O-linked
glycosylation and L-hydroxylation), although these
are not required for calcium binding [17,18]. Struc-
tural studies that have been performed so far on
¢brillin-1 have used NMR methodology [14,19,20].
NMR is particularly suited to the study of single
and multidomain constructs up to approx. 200 ami-
no acids in size, since it can provide detailed infor-
mation on calcium binding in addition to structural
Fig. 1. Domain organisation of ¢brillin-1. A schematic drawing of the structure of cbEGF32-36, modelled on the structure of
cbEGF32-33 is indicated [19]. Calcium ions are shown as red spheres.
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and dynamic properties of the peptide chain.
Although most of the cbEGF-containing constructs
which have been expressed and puri¢ed using the in
vitro refolding method comprise two domains, larger
constructs including a 5-cbEGF domain construct
have been produced which show the expected calci-
um binding properties of correctly folded fragments
(P. Handford, personal communication). Such larger
constructs will be of value for X-ray crystallographic
studies investigating higher order interactions of
cbEGF domains such as those which might occur
within the micro¢bril.
3. Structural role of calcium in multiple tandem
repeats of cbEGFs
Early mutation detection studies identi¢ed a sub-
group of MFS-causing mutations which altered cal-
cium binding consensus residues in cbEGF domains
(Fig. 2) [21^23]. Similar types of mutations had been
observed previously in the cbEGF-containing protein
clotting factor IX (FIX) [24]. A MFS-causing muta-
tion, N2144S, was subsequently shown to cause a
5-fold reduction in calcium binding to isolated
cbEGF32 without disruption of the domain fold
[25]. This result con¢rmed that defective binding
caused by the loss of a calcium ligand could result
in the Marfan syndrome and emphasised the key role
of calcium for ¢brillin function, since only one out of
43 predicted calcium binding sites was disrupted by
the missense mutation. These data prompted an in-
vestigation into ¢brillin cbEGF structure to deter-
mine the precise role of calcium. The in vitro refold-
ing method described above was used to produce
large quantities of a puri¢ed cbEGF domain pair
for structure determination [13].
The solution structure of the cbEGF32-33 domain
pair identi¢ed a rigid rod-like arrangement of the
two domains, which was stabilised by interdomain
calcium binding and hydrophobic interactions [19].
This structure thus identi¢ed a key role for calcium
in the stabilisation of interdomain cbEGF interac-
tions. Multiple tandem repeats of cbEGFs within
¢brillin-1 were predicted to form similar rod shaped
structures (Fig. 1), since both the linker sequence
between tandem cbEGF repeats and residues directly
involved in stabilising the linear arrangement in
cbEGF32-33 are highly conserved in all ¢brillin-1
cbEGF pairs. This prediction was supported by hy-
drodynamic studies on full-length and recombinant
fragments of ¢brillin-1 which demonstrated length
and width measurements consistent with a role for
calcium in maintaining the extended rod-like confor-
mation of cbEGF domains [26]. In addition, the
backbone dynamics properties of the calcium bound
form of cbEGF32-33 showed that the peptide chain
in close proximity to the cbEGF33 calcium binding
site was the most stable region of the domain pair
[27]. Collectively, these data suggested that MFS-
causing mutations which altered the properties of
the calcium binding site located in the interdomain
region of two cbEGF domains (Fig. 2) would have
Fig. 2. Calcium binding mutations identi¢ed in MFS patients.
MFS mutations which change calcium binding consensus resi-
dues are shown mapped onto a pair of cbEGF domains [22,23].
Mutated residues shown located in the N-terminal domain rep-
resent changes which occur in a cbEGF domain adjacent to a
heterologous ¢brillin-1 domain; those located in the C-terminal
domain occur in the context of a cbEGF pair. Calcium binding
consensus residues are shown in red with the predicted ligand
arrangement for calcium indicated. Cysteine residues are shown
in yellow and disulphide bonds indicated with a dashed line.
Residues involved in the hydrophobic packing interaction be-
tween cbEGF domains are shown in blue. The aromatic residue
used to monitor calcium binding in NMR assays is indicated
with an asterisk in each domain.
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signi¢cant conformational e¡ects on the rod-like
linkage, and may therefore have long range e¡ects
on the structure of a contiguous set of cbEGF do-
mains.
4. Calcium confers resistance to proteolysis on
¢brillin-1
A number of studies have shown that the presence
of calcium ions signi¢cantly protects full-length or
recombinant fragments of ¢brillin-1 from proteolysis
by trypsin, elastase, endoproteinase Glu-C, plasmin
and matrix metalloproteinases [28^31]. This e¡ect is
metal ion speci¢c, as can be demonstrated by the
analysis of tryptic digests of 35S-labelled ¢brillin-1
performed in the presence of EGTA, calcium or
magnesium (Fig. 3). These data are in accordance
with a key structural role for calcium in rigidifying
the interdomain linkages between sequential cbEGF
domains as discussed in the previous section. The
presence of MFS-causing (N548I, E1073K,
E2447K) and protein engineered (N2183S) calcium
binding mutations within recombinant multidomain
fragments of ¢brillin caused the introduction of pro-
tease susceptible sites [29^31]. One of these (E1073K)
caused the appearance of a protease sensitive site in
the domain adjacent to the mutated amino acid, sug-
gesting long range e¡ects caused by defective calcium
binding [29]. Collectively these experiments demon-
strate that signi¢cant structural changes occur as a
consequence of disrupting individual calcium binding
sites within ¢brillin-1.
5. Calcium dependent structure of 10^12 nm
micro¢brils
It was previously shown by Kielty and Shuttle-
worth that calcium stabilised micro¢bril architecture
[32]. In the absence of calcium, the morphology of
micro¢brils becomes di¡use and much less well de-
¢ned. To demonstrate that the solution structure of
an isolated cbEGF pair was of physiological rele-
vance to the structure of ¢brillin within the micro-
¢bril, calcium chelation experiments were performed
on puri¢ed micro¢brils from a human ¢broblast line
MSU-1.1 [33]. Structural data predicted that removal
of calcium from tandem repeats of cbEGF domains
would result in a loss of both the calcium dependent
extended conformation and rigidity of the structure.
Quantitative measurement of the bead to bead perio-
dicity and curvature of the micro¢bril population
revealed clear di¡erences in the presence and absence
of calcium. In the absence of calcium, micro¢brils
had a shortened bead to bead periodicity and were
markedly curved rather than linear. They also exhib-
ited a less well de¢ned morphology (Fig. 4). These
e¡ects were reversed by the re-addition of calcium,
but not magnesium to micro¢bril populations con-
¢rming the dependence of ultrastructure on calcium.
6. Models for micro¢bril organisation: staggered
versus unstaggered arrangements
A knowledge of the structural dimensions of a
cbEGF pair (and more recently a TB domain) to-
gether with the observed beaded periodicity of the
micro¢bril (approx. 50^55 nm), has allowed predic-
tions regarding the arrangement of ¢brillin molecules
within the micro¢bril to be made [14,19]. The pre-
dicted molecular dimensions of 43 cbEGFs and seven
TB domains approximates to 140 nm. These mea-
surements indicate that the ¢brillin monomer must
span two or three interbead regions of the micro¢bril
if ¢brillin adopts the extended conformation sug-
Fig. 3. Calcium dependent protection of ¢brillin-1 against pro-
teolysis. Immunoprecipitated 35S-labelled ¢brillin-1 derived from
normal ¢broblasts was treated in a ¢nal volume of 50 Wl con-
taining 100 mM Tris-HCl, pH 8.2 at room temperature with
(1) 5 mM EGTA (EGTA) for 20 min followed by (2) 10 mM
CaCl2 (Ca2) or 10 mM MgCl2 (Mg2) and a further 20 min
incubation and (3) incubation with 20 ng trypsin for 15 min at
37‡C. The additions were varied as tabulated where (3) indi-
cates the substitution of the reagent by water. The position of
¢brillin-1 is indicated (F).
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gested by the structure of a cbEGF pair. A parallel
staggered organisation has been proposed to account
for immunolocalisation data which showed that
monoclonal antibodies with di¡erent epitopes la-
belled the micro¢bril with the same periodicity
[19,34]. An alternative model has been proposed
based on a parallel unstaggered organisation of ¢-
brillin monomers [35]. However, this is consistent
with the observed periodicity of micro¢brils only if
a large proportion of the ¢brillin sequence folds back
on itself. Current structural data obtained for both
the cbEGF and TB domains do not reveal an ob-
vious mechanism for this; however, it remains pos-
sible that structural analyses of other regions of ¢-
brillin will identify su⁄ciently £exible regions.
Recent studies which identi¢ed transglutaminase
cross-link sites in ¢brillin-1 [36], and a 0.33-D stagger
in supramolecular assemblies of micro¢brils [37], do
not formally distinguish between the models since
these data may re£ect higher order interactions be-
tween micro¢brils rather than ¢brillin interactions
within a given micro¢bril. Whichever model is cor-
rect, calcium has a crucial role in stabilising micro-
¢bril architecture. The role of calcium binding to
cbEGF domains within ¢brillin may be to facilitate
lateral alignment and assembly of monomers. Since
one calcium ligand remains unde¢ned within each
cbEGF domain, it is possible that cross-strand don-
ation of a protein ligand occurs to stabilise the
supramolecular assembly of ¢brillin. Further struc-
tural studies of multidomain constructs are in pro-
gress to try and identify whether or not such inter-
actions occur.
7. Dissociation constants for calcium are variable in
¢brillin-1
Analysis of the calcium binding properties of a
¢brillin cbEGF32-33 pair revealed a weak site in
the N-terminal cbEGF domain and a higher a⁄nity
site in the C-terminal module located in the interdo-
main region [13]. A 1H-NMR based assay was used
for calcium binding. This measured the displacement
of a calcium dependent resonance corresponding to
the conserved aromatic residue of the calcium bind-
ing consensus sequence (Fig. 2). This method has
been used widely to analyse the calcium binding
Fig. 4. Calcium dependence of micro¢bril architecture. Morphology of human dermal ¢broblast micro¢brils extracted and puri¢ed
in the presence of 10 mM CaCl2 and incubated for equivalent times in (A) 10 mM CaCl2 and (B) 10 mM EGTA. Note the re-
duced beaded periodicity and curved morphology of EGTA treated micro¢brils. Micro¢brils are viewed at the same magni¢cation.
Bar = 100 nm.
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properties of other cbEGF-containing proteins [4,5].
Further analysis of the calcium binding properties of
di¡erent ¢brillin cbEGF domain pairs has revealed
considerable variation in Kd values for the interdo-
main calcium binding site ranging from 30 WM to
350 WM [13,15,38]. A heterologous domain pair com-
prising TB6-cbEGF32 was found to have a low af-
¢nity site (mM range) suggesting a di¡erent structur-
al role for calcium in this domain context [16]. In
support of this the TB6-cbEGF32 domain pair did
not show calcium dependent resistance to proteoly-
sis, unlike cbEGF32-33 [31]. Other calcium binding
studies performed on multidomain constructs have
revealed moderate a⁄nities for calcium (250^500
WM) [17,35]. These values, measured by equilibrium
dialysis, indicate an average Kd for the fragment
rather than individual values of each cbEGF do-
main.
The physiological signi¢cance of the variation in
calcium binding properties is unknown but may be
important for micro¢bril assembly and/or the biome-
chanical properties of micro¢brils within tissues. It is
interesting to note that the cbEGF domain with the
highest recorded a⁄nity so far is cbEGF13 [38]. This
is located in the region of ¢brillin-1 where mutations
(including those which speci¢cally disrupt calcium
binding) cause the most severe form of disease, neo-
natal Marfan syndrome [39]. Whatever the function
of this region, rigidi¢cation of the cbEGF12-13 link-
age appears to be essential. In contrast an N2144S
calcium binding mutation has been detected which
disrupts an already weak binding site in cbEGF 32
(see section above) [16]. Thus the mechanism by
which this mutation causes disease appears di¡erent
from other calcium binding mutations which occur in
the context of a cbEGF pair. It has been proposed
that the linkage between cbEGF32 and the N-termi-
nal domain TB6 is £exible and this mutation acts by
disrupting the biomechanical properties of this re-
gion [16].
8. Future studies
Recent studies have identi¢ed a key role for calci-
um in maintaining the structural integrity of ¢brillin-
1 within 10^12 nm micro¢brils. Further studies are
required to establish calcium binding properties of
other regions of ¢brillin-1 and identify the mecha-
nism by which calcium binding to cbEGF domains
may exert long range e¡ects on ¢brillin-1 structure.
Structural analyses of multidomain constructs will be
required to establish whether or not calcium has a
role in stabilising higher order interactions within the
micro¢bril. In addition, in order to interpret the
functional consequences of disrupting speci¢c calci-
um binding sites within ¢brillin-1 (as occurs in a
subgroup of MFS-causing mutations), the mecha-
nism of assembly of the micro¢bril needs to be iden-
ti¢ed. The lack of a simple assay has made such
investigations di⁄cult, but recent studies have iden-
ti¢ed some potential intermediates in assembly [40^
42]. Interdisciplinary studies such as those described
will be required to understand ¢brillin-1 function in
connective tissue and pathogenic mechanisms which
cause the Marfan syndrome.
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